The purpose of this study was to standardize therapy monitoring of hepatic metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) during the course of somatostatin receptor radionuclide therapy (SRRT). In 21 consecutive patients with nonresectable hepatic metastases of GEP-NETs, chromogranin A (CgA) and 68 Ga-DOTATOC PET/CT were compared before and after the last SRRT. On 68 Ga-DOTATOC PET/CT, the maximum standard uptake values (SUV max ) of normal liver and hepatic metastases were calculated. In addition, the volumes of hepatic metastases (volume of interest [VOI]) were measured using four cutoffs to separate normal liver tissue from metastases (SUV max of the normal liver plus 10% [VOI liver+10% ], 20% [VOI liver+20% ], 30%
G ASTROENTEROPANCREATIC NEUROENDOCR-INE TUMORS (GEP-NETs) with a 4 per 100,000 incidence rate 1 commonly originate in the digestive tract as carcinoid tumors (intestine) or as islet cell tumors (pancreas) and tend to metastasize early to the liver before becoming clinically apparent. 2 Because surgery-even involving debulking-is often unsuitable at diagnosis due to bilobar involvement or more to 75% liver parenchymal involvement, therapy of nonresectable liver metastases remains a challenge. 3 Chemotherapy does not and cannot practically offer any benefit in the confrontation of the pure neuroendocrine tumors owing to their extremely slow mitotic rate. Also, interferon-a shows limited benefits in patients with large-volume disease. 4 Somatostatin analogues prove useful for controlling hormone-mediated symptoms but have few antitumor effects. 5 Remaining therapies include thermal ablative therapies (radiofrequency ablation 6 /laserinduced thermotherapy 7 ), transarterial embolization 8 / chemoembolization (TACE) with or without doxorubicineluting beads, 9-11 131 I-labeled metaiodobenzylguanidine (MIBG) therapy, 12 selective internal radiation therapy (SIRT) with or without radiosensitizers, 13, 14 and somatostatin receptor radionuclide therapy (SRRT) given intravenously or intra-arterially with or without means to upregulate somatostatin receptor expression. [15] [16] [17] [18] [19] These therapies, including octreotide (Sandostatin) therapy, can be combined, rendering the choice of appropriate treatment even more difficult. Therefore, therapy response predictors or at least sensitive standardized therapy monitoring is needed to find the optimal therapy. 20 The purpose of this study was to standardize therapy monitoring of hepatic metastases from GEP-NETs by somatostatin receptor positron emission tomography/ computed tomography (PET/CT).
Patients and Methods

Patients
Twenty-one consecutive patients (12 males, 9 females) aged 25 to 87 years (mean 6 SD 61 6 13 years) who underwent 52 SRRTs in nonresectable hepatic metastases owing to GEP-NETs were included in this retrospective study performed at the University Hospital of Dresden. The trial was approved by the local ethics committee.
PET/CT and Laboratory Values
On the same day, 68 Ga-DOTATOC PET/CT was performed and laboratory values, including plasma chromogranin A (CgA), creatinine, hemoglobin, and thrombocyte count, were obtained within 1 month before and 3 months after SRRT.
PET/CT was performed on a 16-slice PET/CT scanner (Biograph 16, Siemens Medical Solutions, Forchheim, Germany) 50 6 12 minutes after injection of 136 6 36 MBq 68 Ga-DOTATOC. The radiopeptide was produced in-house using a 68 Ge/ 68 Ga generator and 14 nmol (20 mg) DOTATOC (BACHEM, Switzerland, Bubendorf). The labeling and purification method is described elsewhere. 21 Imaging included low-dose (, 1 mSv) CT (10 mAs, 120 kV, 16 3 1.5 mm collimation, 0.42 s tube rotation time, 86 mm/s table feed, 3 mm reconstruction increment) performed in shallow respiration for attenuation correction followed by a PET scan in three-dimensional mode with iteratively reconstructed slices of 3 mm.
Therapy
SRRT was performed using the radiopeptide yttrium 90 DOTATOC or lutetium 177 DOTA-TATE intravenously administered in a dosage of 4.3 6 0.5 GBq (range 2.6-5.2 GBq).
For renal radiation protection, an infusion of 2,000 mL of an amino acid solution (lactated Ringer solution [Proteinsteril, B. Braun Medical AG, Sempach, Germany], HEPA 8%, Mg 5-Sulfate [B. Braun Medical AG]) was given to inhibit tubular reabsorption of the radiopeptide. Infusion started 30 minutes before and continued up until 4 hours after administration of the radiopeptide.
Most patients underwent several SRRTs, as follows: 6, 3, 9, 1, and 2 patients underwent 1, 2, 3, 4, and 5 SRRTs, respectively. The interval between therapies averaged 5 6 2 months.
Measurements on PET/CT Images
On PET/CT, maximum standardized uptake values (SUV max ) for both the normal liver tissue and the hepatic tumor burden (hepatic metastases) were measured. In addition, on PET, the total PET-avid (functional) hepatic tumor volume was measured in relation to an SUV threshold that determines which volumetric pixel (voxel) counts as ''malignant.'' For this purpose, on CT images, the liver was extracted (segmented) by manually drawing polygons around the liver, which were copied and adjusted slice by slice. Within the CT-defined liver volume, the total PET volume of hepatic metastases was calculated by adding hepatic PET voxels with an SUV max above a threshold that was supposed to separate normal liver tissue from metastases. As referent threshold, the constant (SUV 5 10) threshold and the liver-dependent thresholds (SUV max of the normal liver plus 10%, 20%, and 30%) were used. Thereby, four volumes of interest (VOI) were defined: VOI 10SUV , VOI liver+10% , VOI liver+20% , and VOI liver+30% .
Statistical Analysis
Baseline values and their changes (D 5 [post-pre]/pre%) for CgA, PET values, and nephro-and myelotoxicity monitoring were correlated using the Pearson and Spearman coefficients for normal and nonnormal distributed variables, respectively. Using the one-sample-ttest, we determined if the relative changes (D) were significantly different from no change (D 5 0%). A level of p 5 .05 was used to indicate statistical significance.
Results
The changes per patient are displayed in Table 1 and summarized in Table 2 . CgA was elevated in all patients (range 33-5,510 U/L) (see Table 2 ). The SUV max for normal liver was relatively constant and in all cases was under the cut-off of 10 SUV, rendering it optimal for separating metastases (SUV max 5 25.0 6 12.2) from normal liver tissue (SUV max 5 7.2 6 1.3). There was no correlation between baseline CgA and all tested PET values.
Fourteen of 21 patients showed a reduction after one therapy ( Figure 1 and Figure 2 ). But changes were more significant, considering all therapies and comparing the last PET with the baseline PET ( Figure 3 and Figure 4 ). Changes were significant (p , .01) for DCgA, DSUV max , DVOI 10SUV , Dhemoglobin, and Dthrombocyte count and Table 2 ). Correlations were found only between DCgA and DVOI 10SUV (r 5 .595; p , .01), DSUV max and DVOI 10SUV (r 5 .629; p , .01), Dhemoglobin and Dthrombocyte counts (r 5 .468; p , .05), and SUV max and DSUV max (r 5 2.446; p , .05).
Discussion
GEP-NET is a rare and heterogeneous disease whose prognosis and therapy response are variable. 5 Thus, therapy monitoring and follow-up are necessary, especially in cases where therapies can provoke potential side effects.
Monitoring of Therapy Response
Currently, the assessment of therapy response is based on a unidimensional measurement (diameter) scoring procedure according to which therapy results are classified in four 22 Often, the classification of the unidimensional measurements cannot match the categorization according to the RECIST criteria, resulting in a loss of information. Therefore, a threedimensional (volumetric) measurement is more desirable, enabling a reproducible and continuous quantification of the response. With 68 Ga-DOTATOC PET/CT, the nature, tumor burden, and therapy response of GEP-NETs can be evaluated in vivo based on the expression of somatostatin receptors (SUV max ) and their volume (eg, VOI 10SUV ). In addition, the dynamics of the receptor expression and volume can be reliably and precisely measured, providing information on growth rates-similar to prostate specific antigen velocity. SUV is standardized, and volumetric PET measurements can be automated owing to the high contrast between normal liver tissue and metastases (see Figures 1 to 4). The PET volumetry is based on the addition of ''malignant'' voxels with an SUV max above a cut-off. The precision of the measurement is given by the voxel resolution (field of view [FOV]/matrix size [512] 3 FOV/ matrix size [512] 3 CT reconstruction increment), which is 0.8 3 0.8 3 3 mm for 40 cm patient diameter (FOV) and 3 mm reconstruction increment. In CT, the liver to metastases contrast is too low and too noisy for a voxel-based segmentation (volumetry) and for standardization and too dependent on the timing of the individual contrast phase. However, despite the high PET contrast between normal tissue and GEP-NET metastases, there is no PET definition for quantifying therapy response. 23 Currently, SUV max is usually used as a follow-up parameter-possibly because it mostly correlates with the degree of malignancy. 24 Furthermore, it is easily measurable and reproducible and does not need any threshold for separating normal liver tissue from metastases. In 18 F-FDG PET/CT, the SUV max reflects the most metabolically active part of the tumor. This part is most ''biologically'' relevant and possibly also more predictive of outcome than the volume. But in contrast to 18 F-FDG PET/CT, the SUV max in 68 Ga-DOTATOC PET/CT exclusively reflects the maximum receptor overexpression, yielding no information on metabolism, volume, or growth rate.
Based on the above, volumetric PET values could show therapy response, whereas SUV max remains constant, thereby underestimating therapy response. In our work, therapy response was found to be underestimated when using the SUV max parameter for therapy monitoring instead of CgA or volumetric PET values (see Figures 1, 3, and 4) .
Another method to monitor therapy response in a digital format is the measurement of specific or nonspecific biochemical markers of GEP-NETs. Among the nonspecific markers (serotonin, neuron-specific enolase, carcinoembryonic antigen, and urinary 5-hydroxyindole-3-acetic acid), CgA is considered the most reliable biomarker reflecting the clinical evolution of NETs. 25 CgA levels were found to correlate with tumor burden 26, 27 and recommended as more specific in the follow-up of such tumors. 28 In our study, no correlation between baseline CgA and volumetric PET values could be observed, suggesting that the CgA value might not reflect a tumor burden. In the detection of GEP-NETs, 111 In octreoscan was shown to be superior to CgA. [29] [30] [31] It has been reported that 68 Ga-DOTATOC PET/CT might be more sensitive than 111 In octreoscan 32, 33 and accordingly leading to the suggestion that CgA levels show less suitability for therapy monitoring compared to 68 Ga-DOTATOC PET/CT in the detection of GEP-NETs. Thus, Figure 3 . PET monitoring of somatostatin receptor radionuclide therapy in a 62-year-old patient with a resected pancreatic neuroendocrine tumor. Response after three therapies: DCgA 5 254%, DSUV max 5 215%, DVOI 10SUV 5 241%, DVOI liver+10% 5 230%, DVOI liver+20% 5 224%, DVOI liver+30% 5 221%. Figure 4 . PET monitoring of somatostatin receptor radionuclide therapy in an 87-year-old patient with liver, lymph node, and bone metastases of a neuroendocrine tumor of unknown origin. Response after three therapies: DCgA 5 281%, D|SUV max 5 258%, DVOI 10SUV 5 297%, DVOI liver+10% 5 287%, DVOI liver+20% 5 288%, DVOI liver+30% 5 291%.
the less sensitive CgA also appears to be less suitable for therapy monitoring than 68 Ga-DOTATOC PET/CT (see Figure 1 ). To our knowledge, there are no studies comparing CgA and 68 Ga-DOTATOC PET/CT for therapy monitoring of GEP-NETs. However, follow-up 68 Ga-DOTATOC PET/CT is required if it needs to be decided if the receptor density is sufficient to continue somatostatin receptor-mediated therapies.
The continuously quantified change in volume is summarized in Table 2 . For VOI 10SUV , the mean decrease (95% CI) in volume was 53 6 33 . Using World Health Organization (WHO) categories, this translates to a response (DVOI 10SUV . 50%) in 13 of 21 patients (62%). These results are similar to those of transarterial chemoembolization (TACE) 9 and SRRT. 17 Although Roche and colleagues reported a response rate of 74% with TACE (12% higher than SRRT in these studies), 9 a comparison between them cannot be done because of different parameters used for therapy monitoring.
Owing to the accumulative effect of radiation and chemotherapy, the time point for response assessment is crucial. However, the continuous character of a volumetric index enables normalization, for example, to the baseline volume, time (change/per time 5 velocity), dosage, or number of interventions, thereby facilitating the comparison between therapies, for example between intravenous and intra-arterial SRRT or between SRRT and SIRT. The volumetric character of the entire hepatic tumor burden is naturally more precise for assessing therapy response than the sum of diameters (RECIST) or the sum of the products of perpendicular diameters (WHO) of selected indicator lesions.
The WHO's response classification does not allow for normalizing responses to depict therapy efficacy more precisely. Also, for dynamic studies, the volumetric index of the tumor burden is naturally more precise than a unidimensional diameter of selected indicator lesions. Thus, 68 Ga-DOTATOC PET/CT should be used for volumentric therapy monitoring.
In a diffuse infiltrated liver, it is difficult to determine the SUV max of normal liver tissue. Thus, it is easier to use an absolute cut-off, which is independent of the individual SUV max in a normal liver, for separating metastases from normal liver tissue. In addition, only the liver-independent volumetric changes were as significant as the changes in CgA and SUV max (see Table 2 ).
Predictive Criteria for Therapy Response
Generally, the malignant potential of GEP-NETs and their response to therapy are difficult to predict. Negative prognostic factors include intact primary tumor, pancreatic site of origin, extensive liver metastases, bone metastases, a poor degree of tumor cell differentiation, and a high Ki-67 proliferative index. 34, 35 However, most authors agree that the most common cause of death in patients with GEP-NETs is hepatic failure from tumor progression and that extra hepatic metastatic disease has no significant effect on the outcome.
Given that 68 Ga-DOTATOC PET/CT visualizes the density and anatomic distribution of somatostatin receptors, it can be simultaneously used to pretest if the expression of somatostatin receptors is sufficient for receptor-mediated radiation therapy. So far, parameters or cut-offs remain undefined for triggering the SRRT procedure. However, in our study, it was shown that the maximum baseline density of receptors reflected by the SUV max correlates with the change in SUV max (r 5 2.446; p , .05) rendering SUV max as the only prediction index for response to SRRT.
Besides the maximum receptor density (SUV max ), the high vascularity of hepatic metastases is associated with a better prognosis and response to therapy. 36, 37 This suggests that local (selective) application increases the therapeutic efficacy and should be preferred over systemic application as recommended by McStay and colleagues and Limouris and colleagues. 16, 17 In the study by McStay and colleagues, the subgroup of patients (n 5 9) who underwent concurrent polyvinyl alcohol particle embolization at the same time as 90 Y-DOTA-lanreotide administration had a better tumor response rate than the patients (n 5 14) who underwent 90 Y-DOTA-lanreotide only. 16 Thus, the selective application-in combination with the cessation of the blood supply through embolization-might explain the success of selective TACE. 10, 36, 38 Therefore, TACE has been recommended as first-line and, eventually, exclusive treatment. 9 Owing to the lack of contrast administration, we could not investigate the influence of the blood supply and vascularity of the hepatic metastases on the therapy response. However, this study shows that systemic SRRT is effective. When intravenously administered, about 30% of the injected activity is lost in the urine within the first few hours and does not contribute to the therapy. Thus, increased efficacy can be increased if the SRRT is directly delivered to the hepatic metastases through intra-arterial infusions, as seen in octeotride 16, 17 and MIBG therapies. 12 
Side Effects
If SRRT is intravenously administered, a substantial proportion of the dose dissipates within the systemic circulation, reducing the amount of agent that reaches the target and increasing radiation exposure to kidneys and bone marrow. Radiation-mediated nephrotoxicity and myelosuppression can also be an issue, 16, 39 depending on the radioisotope applied. De Jong and colleagues reported the development of a myelodysplastic syndrome in 7.5% of patients with different types of somatostatin receptorpositive tumors. 40 A minor increase in creatinine of 10 6 40% was observed, but a more significant decrease in hemoglobin (14 6 9 [10-19]%) and thrombocyte counts (26 6 23 [15-38] %) (see Table 1 ). There was no correlation between the changes in hemoglobin and creatinine, so damage to the kidney with consecutive reduction in the release of erythropoietin cannot explain the anemia observed. No correlation was depicted between hemoglobin or thrombocyte counts and volumetric PET values-neither for the baseline values nor for the changes. This makes a tumor volume-associated (paraneoplastic) anemia unlikely. Given that the changes in hemoglobin parallel the changes in thrombocyte count, this might suggest a myelotoxic effect. Therefore, a selective intraarterial administration of SRRT should be preferred to increase efficiency and decrease side effects. 16, 17 
Limitations
We could not correlate the changes in PET with the survival rate because all patients were still alive at the end of the study. Owing to the diffuse character of the hepatic metastases and lack of contrast media in CT, we could not determine a diameter (RECIST criteria, nonmeasurable disease). We could not correlate PET changes and morphologic changes according to the WHO criteria.
Conclusion
The monitoring of an in vivo GEP-NET therapy response is achieved using 68 Ga-DOTATOC PET/CT, based on the nature and tumor burden and assessed by means of the expression of somatostatin receptors (SUV max ) and their volume (VOI 10SUV ). SUV can be standardized and volumetric PET measurements can be done owing to the high contrast between normal liver tissue and metastases. Furthermore, the dynamics of the receptor expression and volume can be reliably and precisely measured, providing valuable information on growth rates. 68 Ga-DOTATOC PET/CT allows volumetric therapy monitoring via a recommended 10 SUV based cut-off, separating hepatic metastases from normal liver tissue.
